Drugs / MRM-3379
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07712718 | May → Jul 2026 overdue | — | Mirum Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07209462 | Nov 2025 → Oct 2027 expected | fragile X syndrome | Mirum Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-01 | Mirum Pharmaceuticals, Inc. | Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome mirumpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRM-3379 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07712718 ↗ |
| Route | Oral | “Oral capsule” NCT07209462 ↗ |